Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …

Objectives The aim of this study was to examine the effect of CYP2C19 genotype on clinical
outcomes in patients with coronary artery disease (CAD) who predominantly underwent …

Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Background This guideline addresses the management of patients who are receiving
anticoagulant or antiplatelet therapy and require an elective surgery or procedure. Methods …

It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

Background and Aims Proton pump inhibitors (PPIs) have been associated with adverse
clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre …